Scott M. Lassman was recently recognized by Who's Who Legal as a recommended regulatory attorney in its Life Sciences 2020 guide.

The Who's Who Legal research process is based on recommendations and feedback from eminent private practitioners in the sector as well as from corporate counsel.

On February 27, 2020, Scott M. Lassman presented a webinar on recent developments affecting exclusivity for drugs and biological products. The webinar was hosted by FDANews.

Scott M. Lassman recently was recognized as a leading regulatory attorney in the Who's Who Legal Healthcare 2020 guide.

The Who's Who Legal research process is based on recommendations and feedback from eminent private practitioners in the sector as well as from corporate counsel.

Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."

Scott M. Lassman recently was recognized by LMG Life Sciences as a Regulatory Law Star in the areas of pharmaceutical and medical device regulatory law for 2019.

LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation on October 2, 2019 in Washington, D.C.

Scott M. Lassman recently was recognized by The Best Lawyers in America as one of the leading lawyers in America in the categories of FDA Law and Administrative/Regulatory Law.

Best Lawyers' recognitions are based purely on the feedback received from lawyers already highlighted in the publication.

Lassman Law+Policy was privileged to represent Braeburn, Inc. (with co-counsel Goodwin) in securing this U.S. District Court ruling overturning an FDA decision on 3-year exclusivity as unreasonable and arbitrary and capricious. The decision, issued on July 22, 2019, orders FDA to reconsider "with deliberate speed" Braeburn's application for approval of an innovative new injectable treatment for opioid use disorder. Read all about it here.